Your browser doesn't support javascript.
loading
TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3.
Wen, Jiaqi; Wang, Qiuke; Zhang, Wenyi; Wang, Weizhang.
Afiliación
  • Wen J; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
  • Wang Q; Guangdong Key Laboratory of Bioactive Drug Research, Guangzhou, China.
  • Zhang W; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
  • Wang W; Guangdong Key Laboratory of Bioactive Drug Research, Guangzhou, China.
FEBS Lett ; 597(24): 3072-3086, 2023 12.
Article en En | MEDLINE | ID: mdl-37873730
Glioblastoma (GBM) is the most common, aggressive, and chemorefractory primary brain tumor in adults. Identifying novel drug targets is crucial for GBM treatment. Here, we demonstrate that tubulin alpha 1a (TUBA1A) is significantly upregulated in GBM compared to low-grade gliomas (LGG) and normal tissues. High TUBA1A expression is associated with poor survival in GBM patients. TUBA1A knockdown results in mitotic arrest and reduces tumor growth in mice. TUBA1A interacts with the polo-like kinase 3 (PLK3) in the cytoplasm to inhibit its activation. This interaction licenses activation of the anaphase-promoting complex or cyclosome (APC/C) to ensure proper Foxm1-mediated metaphase-to-anaphase transition and mitotic exit. Overall, our findings demonstrate that targeting TUBA1A attenuates GBM cell growth by suppressing mitotic progression in a PLK3-dependent manner.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / Proteínas de Ciclo Celular Límite: Animals / Humans Idioma: En Revista: FEBS Lett Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / Proteínas de Ciclo Celular Límite: Animals / Humans Idioma: En Revista: FEBS Lett Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido